Diabetes mellitus type 2
|Diabetes mellitus type 2|
|Classification and external resources|
Universal blue circle symbol for diabetes.
Diabetes mellitus type 2 (formerly noninsulin-dependent diabetes mellitus (NIDDM) or adult-onset diabetes) is a metabolic disorder that is characterized by high blood glucose in the context of insulin resistance and relative insulin deficiency. This is in contrast to diabetes mellitus type 1, in which there is an absolute insulin deficiency due to destruction of islet cells in the pancreas. The classic symptoms are excess thirst, frequent urination, and constant hunger. Type 2 diabetes makes up about 90% of cases of diabetes with the other 10% due primarily to diabetes mellitus type 1 and gestational diabetes. Obesity is thought to be the primary cause of type 2 diabetes in people who are genetically predisposed to the disease.
Type 2 diabetes is initially managed by increasing exercise and dietary modification. If blood glucose levels are not adequately lowered by these measures, medications such as metformin or insulin may be needed. In those on insulin, there is typically the requirement to routinely check blood sugar levels.
Rates of type 2 diabetes have increased markedly over the last 50 years in parallel with obesity: As of 2010 there are approximately 285 million people with the disease compared to around 30 million in 1985. Long-term complications from high blood sugar can include heart disease, strokes, diabetic retinopathy where eyesight is affected, kidney failure which may require dialysis, and poor circulation in the limbs leading to amputations. The acute complication of ketoacidosis, a feature of type 1 diabetes, is uncommon. However, nonketotic hyperosmolar coma may occur.
Signs and symptoms
The classic symptoms of diabetes are polyuria (frequent urination), polydipsia (increased thirst), polyphagia (increased hunger), and weight loss. Other symptoms that are commonly present at diagnosis include: a history of blurred vision, itchiness, peripheral neuropathy, recurrent vaginal infections, and fatigue. Many people, however, have no symptoms during the first few years and are diagnosed on routine testing. People with type 2 diabetes mellitus may rarely present with nonketotic hyperosmolar coma (a condition of very high blood sugar associated with a decreased level of consciousness and low blood pressure).
Type 2 diabetes is typically a chronic disease associated with a ten-year-shorter life expectancy. This is partly due to a number of complications with which it is associated, including: two to four times the risk of cardiovascular disease, including ischemic heart disease and stroke; a 20-fold increase in lower limb amputations, and increased rates of hospitalizations. In the developed world, and increasingly elsewhere, type 2 diabetes is the largest cause of nontraumatic blindness and kidney failure. It has also been associated with an increased risk of cognitive dysfunction and dementia through disease processes such as Alzheimer's disease and vascular dementia. Other complications include: acanthosis nigricans, sexual dysfunction, and frequent infections.
The development of type 2 diabetes is caused by a combination of lifestyle and genetic factors. While some are under personal control, such as diet and obesity, others, such as increasing age, female gender, and genetics, are not. A lack of sleep has been linked to type 2 diabetes. This is believed to act through its effect on metabolism. The nutritional status of a mother during fetal development may also play a role, with one proposed mechanism being that of altered DNA methylation.
A number of lifestyle factors are known to be important to the development of type 2 diabetes, including: obesity (defined by a body mass index of greater than thirty), lack of physical activity, poor diet, stress, and urbanization. Excess body fat is associated with 30% of cases in those of Chinese and Japanese descent, 60-80% of cases in those of European and African descent, and 100% of Pima Indians and Pacific Islanders. Those who are not obese often have a high waist–hip ratio.
Dietary factors also influence the risk of developing type 2 diabetes. Consumption of sugar-sweetened drinks in excess is associated with an increased risk. The type of fats in the diet are also important, with saturated fats and trans fatty acids increasing the risk and polyunsaturated and monounsaturated fat decreasing the risk. Eating lots of white rice appears to also play a role in increasing risk. A lack of exercise is believed to cause 7% of cases.
Most cases of diabetes involve many genes, with each being a small contributor to an increased probability of becoming a type 2 diabetic. If one identical twin has diabetes, the chance of the other developing diabetes within his lifetime is greater than 90% while the rate for nonidentical siblings is 25-50%.As of 2011, more than 36 genes have been found that contribute to the risk of type 2 diabetes. All of these genes together still only account for 10% of the total heritable component of the disease. The TCF7L2allele, for example, increases the risk of developing diabetes by 1.5 times and is the greatest risk of the common genetic variants. Most of the genes linked to diabetes are involved in beta cell functions.
There are a number of rare cases of diabetes that arise due to an abnormality in a single gene (known as monogenic forms of diabetes or "other specific types of diabetes"). These include maturity onset diabetes of the young (MODY), Donohue syndrome, and Rabson-Mendenhall syndrome, among others. Maturity onset diabetes of the young constitute 1–5% of all cases of diabetes in young people.
There are a number of medications and other health problems that can predispose to diabetes. Some of the medications include: glucocorticoids, thiazides, beta blockers, atypical antipsychotics, and statins.Those who have previously had gestational diabetes are at a higher risk of developing type 2 diabetes. Other health problems that are associated include: acromegaly, Cushing's syndrome, hyperthyroidism, pheochromocytoma, and certain cancers such as glucagonomas. Testosterone deficiency is also associated with type 2 diabetes.
Type 2 diabetes is due to insufficient insulin production from beta cells in the setting of insulin resistance. Insulin resistance, which is the inability of cells to respond adequately to normal levels of insulin, occurs primarily within the muscles, liver, and fat tissue. In the liver, insulin normally suppresses glucose release. However, in the setting of insulin resistance, the liver inappropriately releases glucose into the blood. The proportion of insulin resistance versus beta cell dysfunction differs among individuals, with some having primarily insulin resistance and only a minor defect in insulin secretion and others with slight insulin resistance and primarily a lack of insulin secretion.
Other potentially important mechanisms associated with type 2 diabetes and insulin resistance include: increased breakdown of lipids within fat cells, resistance to and lack of incretin, high glucagon levels in the blood, increased retention of salt and water by the kidneys, and inappropriate regulation of metabolism by the central nervous system. However, not all people with insulin resistance develop diabetes, since an impairment of insulin secretion by pancreatic beta cells is also required.
|Condition||2 hour glucose||Fasting glucose||HbA1c|
|Normal||<7.8 (<140)||<6.1 (<110)||<6.0|
|Impaired fasting glycaemia||<7.8 (<140)||≥ 6.1(≥110) & <7.0(<126)||6.0–6.4|
|Impaired glucose tolerance||≥7.8 (≥140)||<7.0 (<126)||6.0–6.4|
|Diabetes mellitus||≥11.1 (≥200)||≥7.0 (≥126)||≥6.5|
- fasting plasma glucose ≥ 7.0 mmol/l (126 mg/dl)
- with a glucose tolerance test, two hours after the oral dose a plasma glucose ≥ 11.1 mmol/l (200 mg/dl)
A random blood sugar of greater than 11.1 mmol/l (200 mg/dL) in association with typical symptoms or a glycated hemoglobin (HbA1c) of greater than 6.5% is another method of diagnosing diabetes. In 2009 an International Expert Committee that included representatives of the American Diabetes Association (ADA), the International Diabetes Federation (IDF), and the European Association for the Study of Diabetes (EASD) recommended that a threshold of ≥6.5% HbA1c should be used to diagnose diabetes. This recommendation was adopted by the American Diabetes Association in 2010. Positive tests should be repeated unless the person presents with typical symptoms and blood sugars >11.1 mmol/l (>200 mg/dl).
Threshold for diagnosis of diabetes is based on the relationship between results of glucose tolerance tests, fasting glucose or HbA1c and complications such as retinal problems. A fasting or random blood sugar is preferred over the glucose tolerance test, as they are more convenient for people. HbA1c has the advantages that fasting is not required and results are more stable but has the disadvantage that the test is more costly than measurement of blood glucose. It is estimated that 20% of people with diabetes in the United States do not realize that they have the disease.
Diabetes mellitus type 2 is characterized by high blood glucose in the context of insulin resistance and relative insulin deficiency. This is in contrast to diabetes mellitus type 1 in which there is an absolute insulin deficiency due to destruction of islet cells in the pancreas and gestational diabetes mellitus that is a new onset of high blood sugars in associated with pregnancy. Type 1 and type 2 diabetes can typically be distinguished based on the presenting circumstances. If the diagnosis is in doubt antibody testing may be useful to confirm type 1 diabetes and C-peptide levels may be useful to confirm type 2 diabetes, with C-peptide levels normal or high in type 2 diabetes, but low in type 1 diabetes.
No major organization recommends universal screening for diabetes as there is no evidence that such a program would improve outcomes. Screening is recommended by the United States Preventive Services Task Force in adults without symptoms whose blood pressure is greater than 135/80 mmHg. For those whose blood pressure is less, the evidence is insufficient to recommend for or against screening. The World Health Organization recommends only testing those groups at high risk. High-risk groups in the United States include: those over 45 years old; those with a first degree relative with diabetes; some ethnic groups, including Hispanics, African-Americans, and Native-Americans; a history of gestational diabetes; polycystic ovary syndrome; excess weight; and conditions associated with metabolic syndrome.
Onset of type 2 diabetes can be delayed or prevented through proper nutrition and regular exercise. Intensive lifestyle measures may reduce the risk by over half. The benefit of exercise occurs regardless of the person's initial weight or subsequent weight loss. Evidence for the benefit of dietary changes alone, however, is limited, with some evidence for a diet high in green leafy vegetables and some for limiting the intake of sugary drinks. In those with impaired glucose tolerance, diet and exercise either alone or in combination with metformin or acarbose may decrease the risk of developing diabetes. Lifestyle interventions are more effective than metformin.
Management of type 2 diabetes focuses on lifestyle interventions, lowering other cardiovascular risk factors, and maintaining blood glucose levels in the normal range. Self-monitoring of blood glucose for people with newly diagnosed type 2 diabetes was recommended by the British National Health Service in 2008, however the benefit of self monitoring in those not using multi-dose insulin is questionable. Managing other cardiovascular risk factors, such as hypertension, high cholesterol, and microalbuminuria, improves a person's life expectancy. Intensive blood pressure management (less than 130/80 mmHg) as opposed to standard blood pressure management (less than 140–160/85–100 mmHg) results in a slight decrease in stroke risk but no effect on overall risk of death.
Intensive blood sugar lowering (HbA1c<6%) as opposed to standard blood sugar lowering (HbA1c of 7–7.9%) does not appear to change mortality. The goal of treatment is typically an HbA1c of less than 7% or a fasting glucose of less than 6.7 mmol/L (120 mg/dL) however these goals may be changed after professional clinical consultation, taking into account particular risks of hypoglycemia and life expectancy. It is recommended that all people with type 2 diabetes get regular ophthalmology examination. Treating gum disease in those with diabetes may result in a small improvement in blood sugar levels.
A proper diet and exercise are the foundations of diabetic care, with a greater amount of exercise yielding better results. Aerobic exercise leads to a decrease in HbA1c and improved insulin sensitivity. Resistance training is also useful and the combination of both types of exercise may be most effective. A diabetic diet that promotes weight loss is important. While the best diet type to achieve this is controversial a low glycemic index diet has been found to improve blood sugar control. Culturally appropriate education may help people with type 2 diabetes control their blood sugar levels, for up to six months at least. If changes in lifestyle in those with mild diabetes has not resulted in improved blood sugars within six weeks, medications should then be considered. There is not enough evidence to determine if lifestyle interventions affect mortality in those who already have DM.
There are several classes of anti-diabetic medications available. Metformin is generally recommended as a first line treatment as there is some evidence that it decreases mortality; however, this conclusion is questioned. A second oral agent of another class may be used if metformin is not sufficient. Other classes of medications include: sulfonylureas, nonsulfonylurea secretagogues, alpha glucosidase inhibitors, thiazolidinediones, glucagon-like peptide-1 analog, and dipeptidyl peptidase-4 inhibitors. Rosiglitazone, a thiazolidinedione, has not be found to improve long term outcomes even though it improves blood sugar levels. Additionally it is associated with increased rates of heart disease and death. Metformin should not be used in those with severe kidney or liver problems. Injections of insulin may either be added to oral medication or used alone.
Most people do not initially need insulin. When it is used, a long-acting formulation is typically added at night, with oral medications being continued. Doses are then increased to effect (blood sugar levels being well controlled). When nightly insulin is insufficient twice daily insulin may achieve better control. The long acting insulins glargine and detemir are equally safe and effective, and do not appear much better than neutral protamine Hagedorn (NPH) insulin, but as they are significantly more expensive, they are not cost effective.[note 1] In those who are pregnant insulin is generally the treatment of choice. Angiotensin-converting enzyme inhibitors (ACEi) prevent kidney disease and improve outcomes in those with diabetes.
Weight loss surgery in those who are obese is an effective measure to treat diabetes. Many are able to maintain normal blood sugar levels with little or no medications following surgery and long-term mortality is decreased. There however is some short-term mortality risk of less than 1% from the surgery. The body mass index cutoffs for when surgery is appropriate are not yet clear. It is recommended that this option be considered in those who are unable to get both their weight and blood sugar under control.
Globally as of 2010 it was estimated that there were 285 million people with type 2 diabetes making up about 90% of diabetes cases. This is equivalent to about 6% of the world's adult population. Diabetes is common both in the developed and the developing world. It remains uncommon, however, in the underdeveloped world.
Women seem to be at a greater risk as do certain ethnic groups, such as South Asians, Pacific Islanders, Latinos, and Native Americans. This may be due to enhanced sensitivity to a Western lifestyle in certain ethnic groups. Traditionally considered a disease of adults, type 2 diabetes is increasingly diagnosed in children in parallel with rising obesity rates. Type 2 diabetes is now diagnosed as frequently as type 1 diabetes in teenagers in the United States.
Rates of diabetes in 1985 were estimated at 30 million, increasing to 135 million in 1995 and 217 million in 2005. This increase is believed to be primarily due to the global population aging, a decrease in exercise, and increasing rates of obesity. The five countries with the greatest number of people with diabetes as of 2000 are India having 31.7 million, China 20.8 million, the United States 17.7 million, Indonesia 8.4 million, and Japan 6.8 million. It is recognized as a global epidemic by the World Health Organization.
Diabetes is one of the first diseases described with an Egyptian manuscript from c. 1500 BCE mentioning "too great emptying of the urine." The first described cases are believed to be of type 1 diabetes. Indian physicians around the same time identified the disease and classified it as madhumeha or honey urine noting that the urine would attract ants. The term "diabetes" or "to pass through" was first used in 230 BCE by the Greek Appollonius Of Memphis. The disease was rare during the time of the Roman empire with Galen commenting that he had only seen two cases during his career.
Type 1 and type 2 diabetes were identified as separate conditions for the first time by the Indian physicians Sushruta and Charaka in 400-500 AD with type 1 associated with youth and type 2 with being overweight. The term "mellitus" or "from honey" was added by the Briton John Rolle in the late 1700s to separate the condition from diabetes insipidus which is also associated with frequent urination. Effective treatment was not developed until the early part of the 20th century when the Canadians Frederick Banting and Charles Best discovered insulin in 1921 and 1922. This was followed by the development of the long acting NPH insulin in the 1940s.
- "Diabetes Blue Circle Symbol". International Diabetes Federation. 17 March 2006.
- Kumar, Vinay; Fausto, Nelson; Abbas, Abul K.; Cotran, Ramzi S. ; Robbins, Stanley L. (2005). Robbins and Cotran Pathologic Basis of Disease (7th ed.). Philadelphia, Pa.: Saunders. pp. 1194–1195. ISBN 0-7216-0187-1.
- Shoback, edited by David G. Gardner, Dolores (2011). Greenspan's basic & clinical endocrinology (9th ed.). New York: McGraw-Hill Medical. pp. Chapter 17. ISBN 0-07-162243-8.
- Williams textbook of endocrinology. (12th ed.). Philadelphia: Elsevier/Saunders. pp. 1371–1435. ISBN 978-1-4377-0324-5.
- Smyth, S; Heron, A (2006 Jan). "Diabetes and obesity: the twin epidemics". Nature Medicine 12 (1): 75–80. doi:10.1038/nm0106-75. PMID 16397575.
- Fasanmade, OA; Odeniyi, IA, Ogbera, AO (2008 Jun). "Diabetic ketoacidosis: diagnosis and management". African journal of medicine and medical sciences 37 (2): 99–105. PMID 18939392.
- Vijan, S (2010-03-02). "Type 2 diabetes". Annals of internal medicine 152 (5): ITC31–15; quiz ITC316. doi:10.1059/0003-4819-152-5-201003020-01003. PMID 20194231.
- Ripsin CM, Kang H, Urban RJ (January 2009). "Management of blood glucose in type 2 diabetes mellitus". Am Fam Physician 79 (1): 29–36. PMID 19145963.
- Pasquier, F (2010 Oct). "Diabetes and cognitive impairment: how to evaluate the cognitive status?". Diabetes & metabolism. 36 Suppl 3: S100–5. doi:10.1016/S1262-3636(10)70475-4. PMID 21211730.
- Risérus U, Willett WC, Hu FB (January 2009). "Dietary fats and prevention of type 2 diabetes". Progress in Lipid Research 48 (1): 44–51. doi:10.1016/j.plipres.2008.10.002. PMC 2654180. PMID 19032965.
- Touma, C; Pannain, S (2011 Aug). "Does lack of sleep cause diabetes?". Cleveland Clinic journal of medicine 78 (8): 549–58. doi:10.3949/ccjm.78a.10165. PMID 21807927.
- Christian, P; Stewart, CP (2010 Mar). "Maternal micronutrient deficiency, fetal development, and the risk of chronic disease". The Journal of nutrition 140 (3): 437–45. doi:10.3945/jn.109.116327. PMID 20071652.
- Malik, VS; Popkin, BM, Bray, GA, Després, JP, Hu, FB (2010-03-23). "Sugar Sweetened Beverages, Obesity, Type 2 Diabetes and Cardiovascular Disease risk". Circulation 121 (11): 1356–64. doi:10.1161/CIRCULATIONAHA.109.876185. PMC 2862465. PMID 20308626.
- Malik, VS; Popkin, BM, Bray, GA, Després, JP, Willett, WC, Hu, FB (2010 Nov). "Sugar-Sweetened Beverages and Risk of Metabolic Syndrome and Type 2 Diabetes: A meta-analysis". Diabetes Care 33 (11): 2477–83. doi:10.2337/dc10-1079. PMC 2963518. PMID 20693348.
- Hu, EA; Pan, A, Malik, V, Sun, Q (2012-03-15). "White rice consumption and risk of type 2 diabetes: meta-analysis and systematic review". BMJ (Clinical research ed.) 344: e1454. doi:10.1136/bmj.e1454. PMC 3307808. PMID 22422870.
- Lee, I-Min; Shiroma, Eric J; Lobelo, Felipe; Puska, Pekka; Blair, Steven N; Katzmarzyk, Peter T (1 July 2012). "Effect of physical inactivity on major non-communicable diseases worldwide: an analysis of burden of disease and life expectancy". The Lancet 380 (9838): 219–29. doi:10.1016/S0140-6736(12)61031-9. PMID 22818936.
- Herder, C; Roden, M (2011 Jun). "Genetics of type 2 diabetes: pathophysiologic and clinical relevance". European journal of clinical investigation 41 (6): 679–92. doi:10.1111/j.1365-2362.2010.02454.x. PMID 21198561.
- "Monogenic Forms of Diabetes: Neonatal Diabetes Mellitus and Maturity-onset Diabetes of the Young". National Diabetes Information Clearinghouse (NDIC) (National Institute of Diabetes and Digestive and Kidney Diseases, NIH). Retrieved 2008-08-04.
- Bethel, edited by Mark N. Feinglos, M. Angelyn (2008). Type 2 diabetes mellitus : an evidence-based approach to practical management. Totowa, NJ: Humana Press. p. 462. ISBN 978-1-58829-794-5.
- Izzedine, H; Launay-Vacher, V, Deybach, C, Bourry, E, Barrou, B, Deray, G (2005 Nov). "Drug-induced diabetes mellitus". Expert opinion on drug safety 4 (6): 1097–109. doi:10.1517/147403184.108.40.2067. PMID 16255667.
- Sampson, UK; Linton, MF, Fazio, S (2011 Jul). "Are statins diabetogenic?". Current Opinion in Cardiology 26 (4): 342–7. doi:10.1097/HCO.0b013e3283470359. PMC 3341610. PMID 21499090.
- Saad F, Gooren L (March 2009). "The role of testosterone in the metabolic syndrome: a review". The Journal of Steroid Biochemistry and Molecular Biology 114 (1–2): 40–3. doi:10.1016/j.jsbmb.2008.12.022. PMID 19444934.
- Farrell JB, Deshmukh A, Baghaie AA (2008). "Low testosterone and the association with type 2 diabetes". The Diabetes Educator 34 (5): 799–806. doi:10.1177/0145721708323100. PMID 18832284.
- Diabetes mellitus a guide to patient care.. Philadelphia: Lippincott Williams & Wilkins. 2007. p. 15. ISBN 978-1-58255-732-8.
- Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. Geneva: World Health Organization. 2006. p. 21. ISBN 978-92-4-159493-6.
- Vijan, S (March 2010). "Type 2 diabetes". Annals of Internal Medicine 152 (5): ITC31-15. doi:10.1059/0003-4819-152-5-201003020-01003. PMID 20194231.
- World Health Organization. "Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO Consultation. Part 1. Diagnosis and classification of diabetes mellitus". Retrieved 29 May 2007.
- American Diabetes, Association (January 2010). "Diagnosis and classification of diabetes mellitus". Diabetes Care. 33 Suppl 1 (Supplement_1): S62–9. doi:10.2337/dc10-S062. PMC 2797383. PMID 20042775.
- International Expert, Committee (2009 Jul). "International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes". Diabetes Care 32 (7): 1327–34. doi:10.2337/dc09-9033. PMC 2699715. PMID 19502545.
- American Diabetes, Association (January 2012). "Diagnosis and classification of diabetes mellitus". Diabetes Care. 35 Suppl 1: S64–71. doi:10.2337/dc12-s064. PMID 22187472.
- Diabetes mellitus a guide to patient care.. Philadelphia: Lippincott Williams & Wilkins. 2007. p. 201. ISBN 978-1-58255-732-8.
- Valdez R (2009). "Detecting Undiagnosed Type 2 Diabetes: Family History as a Risk Factor and Screening Tool". J Diabetes Sci Technol 3 (4): 722–6. PMC 2769984. PMID 20144319.
- "Screening: Type 2 Diabetes Mellitus in Adults". U.S. Preventive Services Task Force. 2008.
- Raina Elley C, Kenealy T (December 2008). "Lifestyle interventions reduced the long-term risk of diabetes in adults with impaired glucose tolerance". Evid Based Med 13 (6): 173. doi:10.1136/ebm.13.6.173. PMID 19043031.
- Orozco LJ, Buchleitner AM, Gimenez-Perez G, Roqué I Figuls M, Richter B, Mauricio D (2008). "Exercise or exercise and diet for preventing type 2 diabetes mellitus". In Mauricio, Didac. Cochrane Database Syst Rev (3): CD003054. doi:10.1002/14651858.CD003054.pub3. PMID 18646086.
- Schellenberg, ES.; Dryden, DM.; Vandermeer, B.; Ha, C.; Korownyk, C. (Oct 2013). "Lifestyle Interventions for Patients With and at Risk for Type 2 Diabetes: A Systematic Review and Meta-analysis.". Ann Intern Med 159 (8): 543–51. doi:10.7326/0003-4819-159-8-201310150-00007. PMID 24126648.
- O'Gorman, DJ; Krook, A (2011 Sep). "Exercise and the treatment of diabetes and obesity". The Medical clinics of North America 95 (5): 953–69. doi:10.1016/j.mcna.2011.06.007. PMID 21855702.
- Nield L, Summerbell CD, Hooper L, Whittaker V, Moore H (2008). "Dietary advice for the prevention of type 2 diabetes mellitus in adults". In Nield, Lucie. Cochrane Database Syst Rev (3): CD005102. doi:10.1002/14651858.CD005102.pub2. PMID 18646120.
- Carter, P; Gray, LJ, Troughton, J, Khunti, K, Davies, MJ (2010-08-18). "Fruit and vegetable intake and incidence of type 2 diabetes mellitus: systematic review and meta-analysis". BMJ (Clinical research ed.) 341: c4229. doi:10.1136/bmj.c4229. PMC 2924474. PMID 20724400.
- Santaguida PL, Balion C, Hunt D, et al. (August 2005). "Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose" (PDF). Evid Rep Technol Assess (Summ) (128): 1–11. PMID 16194123.
- "Clinical Guideline:The management of type 2 diabetes (update)".
- Farmer, AJ; Perera, R, Ward, A, Heneghan, C, Oke, J, Barnett, AH, Davidson, MB, Guerci, B, Coates, V, Schwedes, U, O'Malley, S (2012 Feb 27). "Meta-analysis of individual patient data in randomised trials of self monitoring of blood glucose in people with non-insulin treated type 2 diabetes". BMJ (Clinical research ed.) 344: e486. doi:10.1136/bmj.e486. PMID 22371867.
- McBrien, K; Rabi, DM; Campbell, N; Barnieh, L; Clement, F; Hemmelgarn, BR; Tonelli, M; Leiter, LA; Klarenbach, SW; Manns, BJ (2012 Aug 6). "Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis". Archives of Internal Medicine 172 (17): 1–8. doi:10.1001/archinternmed.2012.3147. PMID 22868819.
- Boussageon, R; Bejan-Angoulvant, T, Saadatian-Elahi, M, Lafont, S, Bergeonneau, C, Kassaï, B, Erpeldinger, S, Wright, JM, Gueyffier, F, Cornu, C (2011-07-26). "Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials". BMJ (Clinical research ed.) 343: d4169. doi:10.1136/bmj.d4169. PMC 3144314. PMID 21791495.
- Webster, MW (2011 Jul). "Clinical practice and implications of recent diabetes trials". Current Opinion in Cardiology 26 (4): 288–93. doi:10.1097/HCO.0b013e328347b139. PMID 21577100.
- Simpson, TC.; Needleman, I.; Wild, SH.; Moles, DR.; Mills, EJ. (2010). "Treatment of periodontal disease for glycaemic control in people with diabetes.". Cochrane Database Syst Rev (5): CD004714. doi:10.1002/14651858.CD004714.pub2. PMID 20464734.
- Zanuso S, Jimenez A, Pugliese G, Corigliano G, Balducci S (March 2010). "Exercise for the management of type 2 diabetes: a review of the evidence". Acta Diabetol 47 (1): 15–22. doi:10.1007/s00592-009-0126-3. PMID 19495557.
- Davis N, Forbes B, Wylie-Rosett J (June 2009). "Nutritional strategies in type 2 diabetes mellitus". Mt. Sinai J. Med. 76 (3): 257–68. doi:10.1002/msj.20118. PMID 19421969.
- Thomas D, Elliott EJ (2009). "Low glycaemic index, or low glycaemic load, diets for diabetes mellitus". In Thomas, Diana. Cochrane Database Syst Rev (1): CD006296. doi:10.1002/14651858.CD006296.pub2. PMID 19160276.
- Hawthorne, K.; Robles, Y.; Cannings-John, R.; Edwards, A. G. K.; Robles, Yolanda (2008). "Culturally appropriate health education for Type 2 diabetes mellitus in ethnic minority groups". In Robles, Yolanda. Cochrane Database Syst Rev (3): CD006424. doi:10.1002/14651858.CD006424.pub2. PMID 18646153. CD006424.
- Schellenberg, ES; Dryden, DM; Vandermeer, B; Ha, C; Korownyk, C (2013 Oct 15). "Lifestyle interventions for patients with and at risk for type 2 diabetes: a systematic review and meta-analysis.". Annals of internal medicine 159 (8): 543–51. PMID 24126648.
- Boussageon, R; Supper, I; Bejan-Angoulvant, T; Kellou, N; Cucherat, M; Boissel, JP; Kassai, B; Moreau, A; Gueyffier, F; Cornu, C (2012). "Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials.". PLoS medicine 9 (4): e1001204. PMID 22509138.
- Qaseem, A; Humphrey, LL, Sweet, DE, Starkey, M, Shekelle, P, Clinical Guidelines Committee of the American College of, Physicians (2012-02-07). "Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians". Annals of internal medicine 156 (3): 218–31. doi:10.1059/0003-4819-156-3-201202070-00011. PMID 22312141.
- American Diabetes, Association (January 2012). "Standards of medical care in diabetes--2012". Diabetes Care. 35 Suppl 1: S11–63. doi:10.2337/dc12-s011. PMID 22187469.
- Richter, B; Bandeira-Echtler, E; Bergerhoff, K; Clar, C; Ebrahim, SH (2007 Jul 18). "Rosiglitazone for type 2 diabetes mellitus.". The Cochrane database of systematic reviews (3): CD006063. PMID 17636824.
- Chen, X; Yang, L; Zhai, SD (2012 Dec). "Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies.". Chinese medical journal 125 (23): 4301–6. PMID 23217404.
- Swinnen, SG.; Simon, AC.; Holleman, F.; Hoekstra, JB.; Devries, JH. (2011). "Insulin detemir versus insulin glargine for type 2 diabetes mellitus.". Cochrane Database Syst Rev (7): CD006383. doi:10.1002/14651858.CD006383.pub2. PMID 21735405.
- Waugh, N; Cummins, E, Royle, P, Clar, C, Marien, M, Richter, B, Philip, S (2010 Jul). "Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation". Health technology assessment (Winchester, England) 14 (36): 1–248. doi:10.3310/hta14360. PMID 20646668.
- Lv, J; Perkovic, V; Foote, CV; Craig, ME; Craig, JC; Strippoli, GF (2012 Dec 12). "Antihypertensive agents for preventing diabetic kidney disease.". The Cochrane database of systematic reviews 12: CD004136. PMID 23235603.
- Picot, J; Jones, J, Colquitt, JL, Gospodarevskaya, E, Loveman, E, Baxter, L, Clegg, AJ (September 2009). "The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation". Health technology assessment (Winchester, England) 13 (41): 1–190, 215–357, iii–iv. doi:10.3310/hta13410. PMID 19726018.
- Frachetti, KJ; Goldfine, AB (April 2009). "Bariatric surgery for diabetes management". Current Opinion in Endocrinology, Diabetes and Obesity 16 (2): 119–24. doi:10.1097/MED.0b013e32832912e7. PMID 19276974.
- Schulman, AP; del Genio, F, Sinha, N, Rubino, F (2009 Sep-Oct). ""Metabolic" surgery for treatment of type 2 diabetes mellitus". Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 15 (6): 624–31. doi:10.4158/EP09170.RAR. PMID 19625245.
- Colucci, RA (January 2011). "Bariatric surgery in patients with type 2 diabetes: a viable option". Postgraduate Medicine 123 (1): 24–33. doi:10.3810/pgm.2011.01.2242. PMID 21293081.
- Dixon, JB; le Roux, CW; Rubino, F; Zimmet, P (2012 June 16). "Bariatric surgery for type 2 diabetes". Lancet 379 (9833): 2300–11. doi:10.1016/S0140-6736(12)60401-2. PMID 22683132.
- Meetoo, D; McGovern, P, Safadi, R (2007 Sep 13-27). "An epidemiological overview of diabetes across the world". British journal of nursing (Mark Allen Publishing) 16 (16): 1002–7. PMID 18026039.
- Abate N, Chandalia M (2001). "Ethnicity and type 2 diabetes: focus on Asian Indians". J. Diabetes Complicat. 15 (6): 320–7. doi:10.1016/S1056-8727(01)00161-1. PMID 11711326.
- Carulli, L; Rondinella, S, Lombardini, S, Canedi, I, Loria, P, Carulli, N (2005 Nov). "Review article: diabetes, genetics and ethnicity". Alimentary pharmacology & therapeutics. 22 Suppl 2: 16–9. doi:10.1111/j.1365-2036.2005.02588.x. PMID 16225465.
- Wild S, Roglic G, Green A, Sicree R, King H (May 2004). "Global prevalence of diabetes: estimates for the year 2000 and projections for 2030". Diabetes Care 27 (5): 1047–53. doi:10.2337/diacare.27.5.1047. PMID 15111519.
- "Diabetes Fact sheet N°312". World Health Organization. Aug 2011. Retrieved 9 January 2012.
- Ripoll, Brian C. Leutholtz, Ignacio (2011-04-25). Exercise and disease management (2nd ed.). Boca Raton: CRC Press. p. 25. ISBN 978-1-4398-2759-8.
- editor, Leonid Poretsky, (2009). Principles of diabetes mellitus (2nd ed.). New York: Springer. p. 3. ISBN 978-0-387-09840-1.
- Cost-effectiveness as of 2010[update]
|Find more about Diabetes mellitus at Wikipedia's sister projects|
|Definitions and translations from Wiktionary|
|Media from Commons|
|Learning resources from Wikiversity|
|Quotations from Wikiquote|
|Source texts from Wikisource|
|Textbooks from Wikibooks|
- Diabetes mellitus type 2 at the Open Directory Project
- National Diabetes Information Clearinghouse
- Centers for Disease Control (Endocrine pathology)